Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Teva to Acquire Emalex Biosciences for $700M, Adding Registration-Ready Tourette Syndrome Drug Ecopipam

Fineline Cube Apr 30, 2026
Company Deals

Eccogene Files Hong Kong IPO Prospectus with THR-β Agonist ECC4703 Leading Metabolic Disease Pipeline

Fineline Cube Apr 30, 2026
Company Deals

Hengrui Pharmaceuticals Replaces Hansoh as Exclusive Licensee for KiOmed’s Osteoarthritis Drug in Greater China

Fineline Cube Apr 30, 2026
Company Deals

Fosun Pharma and Arcera Life Sciences Forge Strategic Partnership to Bridge Chinese Biotech Innovation with Global Markets

Fineline Cube Apr 29, 2026
Company Deals

Hengrui Pharmaceuticals Partners with Sun Yat-sen University to Integrate Industry-Academia Innovation Ecosystem

Fineline Cube Apr 29, 2026
Policy / Regulatory

NMPA Tightens Post-Marketing Requirements for Conditionally Approved Drugs in China, Mandating Four-Year Confirmatory Studies and Annual Progress Reporting

Fineline Cube Apr 27, 2026
Company Drug

Avistone Biotechnology’s Andatinib Receives China Conditional Approval for EGFR Ex20ins NSCLC

Fineline Cube Apr 30, 2026
Company Drug

BeOne Medicines’ Tislelizumab-Zanidatamab Combo Receives FDA Priority Review for HER2-Positive Gastric Cancer

Fineline Cube Apr 30, 2026
Company Drug

Staidson Pharmaceutical’s Bemiltenase Alfa Earns Orphan Drug Designation from US FDA for Hemophilia Treatment

Fineline Cube Jul 1, 2024

Staidson (Beijing) Pharmaceutical Co., Ltd (SHE: 300204), a biopharmaceutical company based in China, has announced...

Company Deals

Cigna & CMB Life Insurance Partners with Cleveland Clinic Foundation to Enhance Medical Diagnosis for Chinese Patients

Fineline Cube Jul 1, 2024

Cigna & CMB Life Insurance Co., a joint venture between Cigna Corporation, a U.S.-based global...

Company Drug

Grand Pharmaceutical Group Ltd’s SIR-Spheres Set to Reach Wider Patient Base Through MediTrust Health Deal

Fineline Cube Jul 1, 2024

Grand Pharmaceutical Group Ltd (HKG: 0512), a leading pharmaceutical company based in China, has announced...

Company Drug

IASO Biotherapeutics’ RD118 CAR-T Therapy Receives Clinical Trial Approval for Multiple Myeloma

Fineline Cube Jul 1, 2024

IASO Biotherapeutics, a biopharmaceutical company based in China, has announced that it has received tacit...

Company Deals Drug

Yunnan Baiyao Group Secures Global Rights to Kyinno Biotechnology’s Antibody Drug KA-1641

Fineline Cube Jul 1, 2024

Yunnan Baiyao Group Co., Ltd (SHE: 000538), a traditional Chinese medicine (TCM) company based in...

Policy / Regulatory

China’s NHSA Releases 2024 National Reimbursement Drug List Adjustment Plan

Fineline Cube Jul 1, 2024

The National Healthcare Security Administration (NHSA) has published the National Reimbursement Drug List (2024) adjustment...

Company Drug

Henlius Pharmaceutical’s HLX15 Biosimilar Meets Phase I Clinical Endpoints

Fineline Cube Jul 1, 2024

Shanghai Henlius Biotech Co., Ltd (HKG: 2696) has announced the successful completion of a Phase...

Company Drug

CSPC Pharmaceutical’s Enronsubaimab Gets NMPA Nod for Recurrent Cervical Cancer

Fineline Cube Jul 1, 2024

CSPC Pharmaceutical Group Ltd (HKG: 1093), a leading pharmaceutical company based in China, has announced...

Company

Reckitt’s New Shanghai R&D Center to Boost Innovation in Health and Hygiene Products

Fineline Cube Jul 1, 2024

Reckitt (LON: RKT), a UK-based manufacturer of consumer health and hygiene products, is planning to...

Company Drug

Johnson & Johnson Achieves Positive Phase III Results for Nipocalimab in Generalized Myasthenia Gravis

Fineline Cube Jul 1, 2024

Johnson & Johnson (J&J, NYSE: JNJ), a leading US-based healthcare company, has announced positive results...

Company Deals

Hasten Biopharmaceutical Expands into Pan-Asia Regions with Celltrion Asset Acquisition

Fineline Cube Jul 1, 2024

Hasten Biopharmaceutical Co., Ltd, a China-based pharmaceutical company backed by CBC Group, has announced an...

Company Drug

Bio-Thera Solutions’ BAT2094 Wins NMPA Nod for Acute Coronary Syndrome Treatment

Fineline Cube Jul 1, 2024

Bio-Thera Solutions Ltd (SHA: 688177), a biopharmaceutical company based in China, has announced that it...

Company Drug

Takeda’s CEO Weber Eyes Further Partnerships with Chinese Biotechs Amid Innovation Surge

Fineline Cube Jul 1, 2024

Takeda Pharmaceutical Co., (TYO: 4502, NYSE: TAK), a leading Japanese pharmaceutical company, is actively seeking...

Company Drug

Luye Pharma’s Manufacturing Facility Passes FDA Inspection for Paliperidone Palmitate Product

Fineline Cube Jun 28, 2024

Luye Pharma Group (HKG: 2186), a Chinese pharmaceutical company, has announced that it has successfully...

Company Drug

Sirnaomics’ STP707 Shows Promising Results in Phase I Pancreatic Cancer Trial

Fineline Cube Jun 28, 2024

Sirnaomics Ltd (HKG: 2257), a biopharmaceutical company, has announced the successful completion of a Phase...

Company Deals

Shandong Junxiu Biotechnology Partners with Swiss Firm Geistlich to Boost Regenerative Medicine

Fineline Cube Jun 28, 2024

Shandong Junxiu Biotechnology Co., Ltd, a Chinese manufacturer of implantable regenerative medicine devices, has entered...

Company Drug

Genmab and AbbVie’s Epcoritamab Earns FDA Accelerated Approval for Follicular Lymphoma

Fineline Cube Jun 28, 2024

Genmab A/S (NASDAQ: GMAB), a Danish biotechnology company, and its co-development partner AbbVie (NYSE: ABBV),...

Company Deals

AbbVie Bolsters Inflammatory Disease Portfolio with Celsius Therapeutics Acquisition

Fineline Cube Jun 28, 2024

AbbVie (NYSE: ABBV), a major U.S. pharmaceutical company, has announced the acquisition of Celsius Therapeutics...

Company Drug

Novo Nordisk Plans Cautious Wegovy Launch in China to Preserve Global Supply

Fineline Cube Jun 28, 2024

Novo Nordisk (NYSE: NVO; CPH: NOVO-B), a leading healthcare company, has reportedly planned a cautious...

Company Deals

Novo Nordisk Moves to Acquire 2seventy bio’s Hemophilia A Program and Gene-Editing Technology

Fineline Cube Jun 28, 2024

Novo Nordisk (NYSE: NVO; CPH: NOVO-B), a leading Danish biopharmaceutical company, is transitioning from a...

Posts pagination

1 … 332 333 334 … 660

Recent updates

  • Avistone Biotechnology’s Andatinib Receives China Conditional Approval for EGFR Ex20ins NSCLC
  • GE Healthcare Reports 7.4% Q1 Revenue Growth to $5.1B Driven by Imaging and Pharmaceutical Diagnostics Strength
  • GE Healthcare Restructures Imaging Business with $14.6B AIS Segment and New Executive Leadership
  • AstraZeneca Reports 8% Q1 Revenue Growth to $15.3B Driven by Oncology and Rare Disease Strength
  • BeOne Medicines’ Tislelizumab-Zanidatamab Combo Receives FDA Priority Review for HER2-Positive Gastric Cancer
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Avistone Biotechnology’s Andatinib Receives China Conditional Approval for EGFR Ex20ins NSCLC

Company

GE Healthcare Reports 7.4% Q1 Revenue Growth to $5.1B Driven by Imaging and Pharmaceutical Diagnostics Strength

Company

GE Healthcare Restructures Imaging Business with $14.6B AIS Segment and New Executive Leadership

Others

AstraZeneca Reports 8% Q1 Revenue Growth to $15.3B Driven by Oncology and Rare Disease Strength

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.